Equity Overview
Price & Market Data
Price: $1.95
Daily Change: +$0.09 / 4.62%
Daily Range: $1.91 - $1.95
Market Cap: $179,745,200
Daily Volume: 5,736
Performance Metrics
1 Week: 8.14%
1 Month: 2.20%
3 Months: 15.53%
6 Months: -18.06%
1 Year: 145.6%
YTD: 16.98%
Company Details
Employees: 97
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.